Cara Therapeutics (CARA) Misses Q4 EPS by 24c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.56), $0.24 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $14.54 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Wendy's U.S. president to resign, company to create COO role
• Yum! Brands (YUM) PT Lowered to $180 at Argus